ALKERMES (8AK MU) stock market data APIs
€36.9828
0(0%)
as of September 24, 2026
Try our APIs with
free plan!
ALKERMES Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for 8AK.MU.
Prev. Close
36.9828
Open
36.9828
High
36.9828
Low
36.9828
52 wk Range
23.6-48.55
Market Cap
3 126 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ALKERMES data using free add-ons & libraries
Get ALKERMES Fundamental Data
ALKERMES Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ALKERMES News
New
Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290
In September 2026, Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful,...
Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says
Alkermes (ALKS) recent attention-deficit/hyperactivity disorder data increased its management's conf PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
Alkermes ALKS announced positive top-line data from a phase I proof-of-concept study evaluating its novel, investigational orexin 2 receptor (OX2R) agonist, ALKS 7290, for the treatment of attention-d...
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won
Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD. Continue Reading
Get ALKERMES fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
